HUTCHMED Highlights SAFFRON Phase III Lung Cancer Trial Results
The company says ORPATHYS plus TAGRISSO reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO. Median overall survival increased by nearly five months.